|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$7,583,000
|
N/A
|
National Institutes of Health
|
|
Prevention of Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH)
|
261201500018I
|
$2,155,216
|
$2,155,216
|
-, -
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Frameshift peptide vaccine for the prevention Lynch syndrome-associated gastrointestinal cancer HHSN2612015000391 TORFP: 2018-E12 POP: 9/17/2018 to 3/16/2021
|
261201500039I
|
$894,832
|
$894,832
|
-, -
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Exercise Option 1 Preclinical Efficacy Evaluation of the Lipid-Based SMEDDS Formulation of DIM, BR-9001,
|
261201500042I
|
$973,931
|
$973,931
|
-, -
|
IIT RESEARCH INSTITUTE
|
|
Regulatory Support for Cancer Prevention Agent Development
|
261201800017C
|
$2,653,402
|
$2,653,402
|
-, -
|
CCS ASSOCIATES, INC.
|
|
IGF::OT::IGF Topic 374 Phase 1 - Topical Delivery of Nanoformulated Natural Bioactive Chemopreventive Agent in Skin Cancer. September 17, 2018 - June 16, 2019. CAN#8478358
|
261201800019C
|
$288,945
|
$288,945
|
-, -
|
VASCULAR VISION PHARMACEUTICALS COMPANY
|
|
IGF::OT::IGF SBIR Topic 374, Phase I:Sustained Delivery of PARP Inhibitors for Cancer Chemoprevention
|
261201800026C
|
$300,000
|
$300,000
|
-, -
|
THERANANO, LLC
|
|
Task Order #1: Centralized Chemopreventive Agent Repository and Chemistry Support
|
261201800026I
|
$3,758,949
|
$3,758,949
|
-, -
|
MIDWEST RESEARCH INSTITUTE
|
|
Technical Information Research Resources for Cancer Preventive Agent Development
|
261201800030C
|
$2,219,906
|
$2,219,906
|
-, -
|
CCS ASSOCIATES, INC.
|
|
Topic 374 - Phase I - Targeted and Sustained Release Microparticles for Colon Cancer Chemoprevention
|
261201800035C
|
$299,810
|
$299,810
|
-, -
|
ZYMERON CORPORATION
|
|
Linxian nutrition intervention trial follow-up study
|
ZIA CP000112 00377
|
$41,189
|
$30,892
|
Abnet, Christian
|
DCEG (NCI)
|
|
Frederick repository and lab support
|
ZIA CP000112 10313
|
$61,784
|
$61,784
|
Abnet, Christian
|
DCEG (NCI)
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
$94,087
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
|
5R01CA140368-07
|
$369,313
|
$369,313
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-05
|
$382,616
|
$382,616
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
ATBC Study
|
ZIA CP010195 03031
|
$738,165
|
$147,633
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Cancer Prevention and Control Health Disparities Training Program
|
5T32CA078447-18
|
$161,530
|
$32,306
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Inherited bone marrow failure syndromes study
|
ZIA CP010144 07130
|
$1,652,758
|
$330,552
|
Alter, Blanche
|
DCEG (NCI)
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
$225,925
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Bitter Melon Component and Colon Cancer Prevention
|
5R01CA190291-05
|
$544,710
|
$544,710
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
Metro-Minnesota Community Clinical Oncology Program (MM-CCOP)
|
5UG1CA189863-06
|
$2,840,966
|
$1,420,483
|
ANDERSON, DANIEL
|
HEALTHPARTNERS INSTITUTE
|
|
Reducing risk of Anthracycline-related heart failure after childhood cancer
|
5R01CA196854-04
|
$604,525
|
$604,525
|
ARMENIAN, SARO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA042014-29S1
|
$125,000
|
$3,750
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S2
|
$250,000
|
$7,500
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S3
|
$248,625
|
$7,459
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S4
|
$114,251
|
$3,428
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S5
|
$59,693
|
$1,791
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S6
|
$155,422
|
$4,663
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
RNF128 Regulation of TP53 in Barretts Progression
|
5R01CA215596-02
|
$422,751
|
$139,508
|
BEER, DAVID
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Histone Methyltransferases as a Target for Lung Cancer Prevention
|
5R01CA183296-05
|
$731,519
|
$731,519
|
BELINSKY, STEVEN
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
|
Ovarian Cancer Chemoprevention
|
5R01CA196200-04
|
$465,809
|
$465,809
|
BENBROOK, DORIS
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
Targeting HPV Consequences in a Cervical Cancer Clinical Trial
|
5R01CA200126-03
|
$176,894
|
$176,894
|
BENBROOK, DORIS
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
3P30CA013148-46S1
|
$52,084
|
$6,250
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
3P30CA013148-46S2
|
$72,961
|
$8,755
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
3P30CA013148-46S3
|
$91,218
|
$10,946
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
3P30CA013148-46S4
|
$45,500
|
$5,460
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
3P30CA013148-46S5
|
$198,945
|
$23,873
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
5P30CA013148-46
|
$5,104,077
|
$612,489
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
IGF::OT::IGF ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL
|
261201200034I
|
$2,107,122
|
$2,107,122
|
BROWN, POWEL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
SPORE in Lung Cancer
|
3P50CA058187-23S1
|
$61,337
|
$30,669
|
BUNN, PAUL
|
UNIVERSITY OF COLORADO DENVER
|
|
SPORE in Lung Cancer
|
5P50CA058187-23
|
$2,300,000
|
$1,150,000
|
BUNN, PAUL
|
UNIVERSITY OF COLORADO DENVER
|
|
Oncology Training Grant
|
5T32CA009338-40
|
$544,263
|
$272,132
|
BYRD, JOHN
|
OHIO STATE UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA016058-42S1
|
$59,783
|
$2,391
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Optimizing the Impact of Aspirin for Chemoprevention
|
1K07CA218377-01A1
|
$143,546
|
$143,546
|
CAO, YIN
|
WASHINGTON UNIVERSITY
|
|
VHL
|
ZIA CP005803 08290
|
$52,954
|
$5,295
|
Caporaso, Neil
|
DCEG (NCI)
|
|
Nutrition, Biostatistics & Bioinformatics Training Grant
|
5T32CA090301-18
|
$105,821
|
$26,455
|
CARROLL, RAYMOND
|
TEXAS A&M UNIVERSITY
|
|
Identification of novel spermine oxidase (SMOX) inhibitors as probes for an emerging chemoprevention target
|
3R01CA204345-03S1
|
$102,584
|
$102,584
|
CASERO, ROBERT
|
JOHNS HOPKINS UNIVERSITY
|
|
Identification of novel spermine oxidase (SMOX) inhibitors as probes for an emerging chemoprevention target
|
5R01CA204345-03
|
$630,557
|
$630,557
|
CASERO, ROBERT
|
JOHNS HOPKINS UNIVERSITY
|
|
Inflammation and Colorectal Neoplasia
|
5R01CA137178-09
|
$905,211
|
$905,211
|
CHAN, ANDREW
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Molecular basis for dietary chemoprevention
|
3R35CA197707-03S1
|
$105,068
|
$105,068
|
CHAPKIN, ROBERT
|
TEXAS A&M AGRILIFE RESEARCH
|
Total relevant funding to Chemoprevention for this search: $101,789,902
|